ChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. The Company's pipeline comprises various programs, including orphan and rare diseases, immuno-oncology, chronic kidney disease, and other inflammatory and autoimmune diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: CCXI
- CUSIP: 16383L10
- Previous Close: $7.17
- 50 Day Moving Average: $7.34
- 200 Day Moving Average: $6.55
- 52-Week Range: $1.92 - $9.10
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.06
- P/E Growth: 0.00
- Market Cap: $313.12M
- Outstanding Shares: 47,805,000
- Beta: 1.52
- Return on Equity: -71.28%
- Return on Assets: -41.63%
Companies Related to ChemoCentryx:
- Current Ratio: 4.68%
- Quick Ratio: 4.68%
What is ChemoCentryx's stock symbol?
ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."
Where is ChemoCentryx's stock going? Where will ChemoCentryx's stock price be in 2017?
3 brokers have issued 12 month target prices for ChemoCentryx's stock. Their forecasts range from $11.00 to $11.00. On average, they anticipate ChemoCentryx's stock price to reach $11.00 in the next year.
When will ChemoCentryx announce their earnings?
ChemoCentryx is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
What are analysts saying about ChemoCentryx stock?
Here are some recent quotes from research analysts about ChemoCentryx stock:
According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (1/17/2017)
J P Morgan Chase & Co analysts commented, "ChemoCentryx announced a GAAP loss per share of $0.22. Overall, highlights on the call were incremental and the company continues to make steady progress across key programs. Of note, related to CCX168 in ANCA-associated vasculitis (AAV), the company has had initial discussions with US / EU regulatory bodies. Along with the recent strategic partnering with Vifor Pharma, we believe that the potential advancement of CCX168 into phase 3 would provide further validation to the phase 2 datasets (phase 3 program expected to start by YE16; see our thoughts from CLEAR and CLASSIC studies here and here). Looking forward beyond CCX168 in AAV, there are additional catalysts worth monitoring, including early data from CCX168 in aHUS (late-2016; potentially ASN in November) and ORR (3Q) / initial PFS (4Q) data for CCX872." (8/9/2016)
Cowen and Company analysts commented, "Chemocentryx’s Investor Meeting offered a review of lead candidates CCX168 for." (5/19/2016)
Who owns ChemoCentryx stock?
ChemoCentryx's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (4.46%), Renaissance Technologies LLC (0.98%), State Street Corp (0.84%), Oxford Asset Management (0.59%), City Financial Investment Co Ltd (0.31%) and Bogle Investment Management L P DE (0.22%). Company insiders that own ChemoCentryx stock include Bvf Partners L P/Il, Geoffrey M Parker, Ira Klein, James L Tyree, Markus J Cappel, Petrus Bekker, Roger C Lucas, Susan M Kanaya, Thomas A Edwards, Thomas J Schall and Value Fund L P Biotechnology.
Who sold ChemoCentryx stock? Who is selling ChemoCentryx stock?
ChemoCentryx's stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management, Franklin Resources Inc., Keybank National Association OH and State Street Corp. Company insiders that have sold ChemoCentryx stock in the last year include James L Tyree, Markus J Cappel, Petrus Bekker and Roger C Lucas.
Who bought ChemoCentryx stock? Who is buying ChemoCentryx stock?
ChemoCentryx's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, City Financial Investment Co Ltd, Federated Investors Inc. PA, Russell Investments Group Ltd. and Bogle Investment Management L P DE. Company insiders that have bought ChemoCentryx stock in the last two years include Geoffrey M Parker and Thomas A Edwards.
How do I buy ChemoCentryx stock?
Shares of ChemoCentryx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of ChemoCentryx stock cost?
One share of ChemoCentryx stock can currently be purchased for approximately $6.55.